FDA Approves Trial for Stem Cell Treatment for Dry AMD

StemCells, an age-related macular degeneration drug researcher, received FDA to start a clinical trial on the potential treatment for dry age-related macular degeneration, according to a news release.

The trial will evaluate the safety and efficacy of HuCNS-SC cells as a treatment for dry AMD. These cells are a purified population of human neural stem cells that can self-renew and differentiate into the three major cell types. Currently, there is no approved treatment for dry AMD.

Related Articles on Ophthalmology:
Ophthalmologists Have More Musculoskeletal Disorders Than Other Physicians
Researchers Find Simple Surgery Fixes Crossed Eyes
FDA Approves Mobius Therapeutics' Glaucoma Drug

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers

Featured Podcast